<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556996</url>
  </required_header>
  <id_info>
    <org_study_id>HSRRB A-7965</org_study_id>
    <nct_id>NCT02556996</nct_id>
  </id_info>
  <brief_title>Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children</brief_title>
  <official_title>Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Naval Medical Research Unit No. 3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled clinical trial performed in Egyptian
      children 6-18 months of age. The primary aim of the study is to determine the protective
      efficacy of an oral, inactivated whole-cell enterotoxigenic Escherichia coli (ETEC) vaccine
      against diarrhea associated with excretion of ETEC that express a vaccine-shared antigen over
      a one year period of follow-up by active surveillance. The vaccine consists of a mixture of
      five formalin-killed ETEC bacteria expressing prevalent ETEC colonization factors and
      recombinant cholera toxin B-subunit (killed ETEC/rCTB vaccine). The placebo preparation is
      heat-killed Escherichia coli K-12 bacteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first event of diarrhea due to vaccine-preventable ETEC (VP-ETEC) as defined below, and no other copathogen.</measure>
    <time_frame>365-day period starting 14 days after the third vaccination</time_frame>
    <description>Time to first event of diarrhea associated with excretion of VP-ETEC (defined as ETEC expressing heat-labile [LT] and heat-stable enterotoxin [ST], or ST and a vaccine-shared colonization factor [i.e., CFA/I, CS1, CS2, CS3, CS4, and/or CS5]) and no other copathogen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first event of diarrhea due to ST-only ETEC expressing a vaccine-shared CF (ST-VCF-ETEC) as defined below, and no other copathogen..</measure>
    <time_frame>365-day period starting 14 days after the third vaccination</time_frame>
    <description>Time to first event of diarrhea associated with excretion of ST-VCF-ETEC (defined as ETEC expressing ST-only plus any vaccine-shared colonization factor [i.e., CFA/I, CS1, CS2, CS3, CS4, and/or CS5]) and no other copathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All events of diarrhea irrespective of etiology</measure>
    <time_frame>365-day period starting 14 days after the third vaccination</time_frame>
    <description>All events (i.e., initial plus recurrent) of diarrhea associated with excretion of any ETEC, irrespective of phenotype, and no other copathogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG seroconversion</measure>
    <time_frame>Baseline serum specimen is collected before first dose and post-vaccination specimen collected 14 days after third dose</time_frame>
    <description>IgG seroconversion (≥ twofold increase in post-vaccination endpoint titer over baseline) against rCTB and vaccine-specific colonization factors CFA/I, CS2, CS4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgA seroconversion</measure>
    <time_frame>Baseline serum specimen is collected before first dose and post-vaccination specimen collected 14 days after third dose</time_frame>
    <description>IgA seroconversion (≥ twofold increase in post-vaccination endpoint titer over baseline) against rCTB and selected vaccine-specific colonization factors CFA/I, CS2, CS4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of solicited adverse events</measure>
    <time_frame>3-day period after each dose</time_frame>
    <description>(i.e., diarrhea, vomiting, fever by caregiver report, poor feeding, and irritability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Killed ETEC/rCTB vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses administered orally at 2-week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three doses administered orally at 2-week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETEC/rCTB vaccine</intervention_name>
    <description>Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)</description>
    <arm_group_label>Killed ETEC/rCTB vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willingness of parent to have the child participate;

          2. Plans to reside in catchment area continuously for at least one year

        Exclusion Criteria:

          1. Global developmental delay

          2. Severe malnutrition

          3. Chronic bedridden status

          4. Serious chronic disorder requiring chronic medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Savarino, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naval Medical Research Center</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

